ZD6126: A novel small molecule vascular targeting agent

International Journal of Radiation Oncology Biology Physics

Volumn 54, Issue 5, 2002, Pages 1497-1502

  Blakey, David C ^a   Ashton, Susan E ^a   Westwood, F Russell ^a   Walker, Mike ^a   Ryan, Anderson J ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Endothelial cell; Vascular targeting; ZD6126

Indexed keywords

CELLS; DRUG INFUSION; LIVING SYSTEMS STUDIES; PHENOLS; TOXICITY; TUMORS;

CYTOTOXICITY;

ONCOLOGY;

N ACETYLCOLCHINOL PHOSPHATE; PRODRUG;

ANIMAL CELL; CELL SHAPE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG ELIMINATION; DRUG SELECTIVITY; DRUG TARGETING; ENDOTHELIUM CELL; EVALUATION; HALF LIFE TIME; HUMAN; IMPLANTATION; IN VITRO STUDY; IN VIVO STUDY; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR NECROSIS; TUMOR VASCULARIZATION; UMBILICAL VEIN;

3T3 CELLS; ANGIOGENESIS INHIBITORS; ANIMALS; CELL DIVISION; CELL LINE, TRANSFORMED; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FIBROBLASTS; HUMANS; MICE; NECROSIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPHOSPHORUS COMPOUNDS; RATS; RATS, NUDE; TIME FACTORS; UMBILICAL VEINS;

EID: 0036890746     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)03922-6     Document Type: Conference Paper

References (15)

1. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev. 9:1990;267-282.
2. Chaplin D.J., Dougherty G.T. Tumour vasculature as a target for cancer therapy. Br J Cancer. 80:(Suppl. 1):1999;57-64.
3. Gotlieb A.I. The endothelial cytoskeleton Organisation in normal and regenerating endothelium . Toxicol Pathol. 18:1990;603-617.
4. Wong M.K., Gotlieb A.I. Endothelial cell monolayer integrity. I Characterisation of dense peripheral band of microfilaments. Arteriosclerosis. 6:1986;212-219.
5. Morikawa S., Baluk P., Kaidoh T., Haskell A., Jain R.K., McDonald D.M. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumours. Am J Pathol. 160:2002;985-1000.
6. Davies PD, Dougherty GJ, Blakey DC; et al. ZD6126. A Novel Vascular Targeting Agent that Causes Selective Disruption of Tumour Vasculature. Submitted for publication.
7. Galbraith S.M., Chaplin D.J., Lee F., et al. Effects of combretastatin A-4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 21:2001;93-102.
8. Blakey D.C., Westwood F.R., Walker M., et al. Anti-tumour activity of the novel vascular targeting agent ZD6126 in a panel of tumour models. Clin Cancer Res. 8:2002;1974-1983.
9. Blakey D.C., Ashton S.E., Eardley S.E., et al. ZD6126. A novel vascular targeting agent which causes massive necrosis in a range of human tumor xenografts. (Abstr.) Proceedings of the American Association for Cancer Research. 41:2000;329.
10. Blakey D.C., Ashton S.E., Douglas S., et al. Anti-tumour activity of the novel vascular targeting agent ZD6126 in a human lung tumour xenograft model. (Abstr.) Clin Cancer Res. 6:(Supplement):2000;4522S.
11. Burrows F.J., Thorpe P.E. Eradication of large solid tumours in mice with an immunotoxin directed against tumour vasculature. Proc Natl Acad Sci U S A. 90:1993;8996-9000.
12. Huang X.M., Molema G., King S., et al. Tumour infarction in mice by antibody-directed targeting of tissue factor to tumour vasculature. Science. 275:1997;547-550.
13. Blakey D.C., Ashton S.E., Westwood F.R., Ryan A.J. Optimisation of ZD6126 activity in the Calu 6 tumour model. (Abstr.) Proceedings of the American Association for Cancer Research. 43:2002;156.
14. Davies P.D., Hill S.A., Galbraith S.M., et al. ZD6126. A new agent causing selective damage of tumour vasculature. (Abstr.) Proceedings of the American Association for Cancer Research. 41:2000;329.
15. Siemann D.W., Rojiani A.M. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys. 53:2002;164-171.